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Abstract
Background: Although recent studies indicate a crucial role for IL-17A and IL-22 producing T cells in the pathogenesis of
psoriasis, limited information is available on their frequency and heterogeneity and their distribution in skin in situ.
Methodology/Principal Findings: By spectral imaging analysis of double-stained skin sections we demonstrated that IL-17
was mainly expressed by mast cells and neutrophils and IL-22 by macrophages and dendritic cells. Only an occasional IL-
17
pos, but no IL-22
pos T cell could be detected in psoriatic skin, whereas neither of these cytokines was expressed by T cells
in normal skin. However, examination of in vitro-activated T cells by flow cytometry revealed that substantial percentages of
skin-derived CD4 and CD8 T cells were able to produce IL-17A alone or together with IL-22 (i.e. Th17 and Tc17, respectively)
or to produce IL-22 in absence of IL-17A and IFN-c (i.e. Th22 and Tc22, respectively). Remarkably, a significant proportional
rise in Tc17 and Tc22 cells, but not in Th17 and Th22 cells, was found in T cells isolated from psoriatic versus normal skin.
Interestingly, we found IL-22 single-producers in many skin-derived IL-17A
pos CD4 and CD8 T cell clones, suggesting that in
vivo IL-22 single-producers may arise from IL-17A
pos T cells as well.
Conclusions/Significance: The increased presence of Tc17 and Tc22 cells in lesional psoriatic skin suggests that these types
of CD8 T cells play a significant role in the pathogenesis of psoriasis. As part of the skin-derived IL-17A
pos CD4 and CD8 T
clones developed into IL-22 single-producers, this demonstrates plasticity in their cytokine production profile and suggests
a developmental relationship between Th17 and Th22 cells and between Tc17 and Tc22 cells.
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Introduction
Psoriasis is a chronic inflammatory skin disease of unknown
etiology, characterized by T cell infiltrates and epidermal
thickening, due to hyperproliferation of keratinocytes [1,2,3,4].
For many years, psoriasis was considered to be a Th1-mediated
disease, because of the relative increase of circulating and skin-
residing IFN-c-producing T cells [5,6] and the activation of many
IFN-c-induced immune response genes [7]. However, since the
discovery that IL-17A-producing CD4 T cells (Th17) are crucially
involved in the pathogenesis of some mouse autoimmune diseases
[8,9,10], and because psoriasis is often considered an autoimmune
or autoinflammatory disorder, many investigators switched their
attention to Th17 cells as possible main instigators of psoriasis.
Th17 cells have as key features that they produce IL-17A and that
IL-23 is important for their maintenance [11]. Several observa-
tions support the involvement of the IL-23/IL-17A pathway in the
pathogenesis of psoriasis. Mice overexpressing IL23p19 develop
severe inflammation of many organs, including the skin [12].
Intradermal injection of IL-23 in murine skin leads to a type of
skin inflammation that more closely resembles the histopatholog-
ical features of psoriatic skin than skin inflammation induced by
IL-12, a key cytokine for Th1 development [13,14]. Levels of
mRNA for the IL-23p19 and common IL-12/IL-23p40 units, but
not for the IL-12p35 unit, are increased in lesional skin of psoriasis
patients [13,15] and also at protein level IL-23 is more abundantly
expressed [16]. Furthermore, sequence variation in the genes
encoding the common IL-12/23p40 unit and IL-23R is associated
with psoriasis [17,18]. Finally, treatment with a neutralizing IL-
12/23p40 antibody has proven to be a very effective therapeutic
modality for psoriasis patients [19,20,21,22].
With regard to IL-17A, we have previously demonstrated that
many T cell clones from lesional psoriatic skin express IL-17A
mRNA, that the IL-17A mRNA levels in psoriatic skin are much
higher than in symptomless skin [23], and that IL-17A in
combination with IFN-c stimulates the production of inflamma-
tory cytokines in keratinocytes [23]. IL-17A by itself induces the
production of antibacterial peptides by keratinocytes, as well as
angiogenesis, which is interesting to note as high levels of
antibacterial peptides and hyperplasia of blood vessels are typical
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involvement of Th17 cells in psoriasis, as early disease improve-
ment in patients treated with the TNF-a inhibitor etanercept
coincides in time with the reduction of Th17 gene products and
downstream effector molecules [26].
IL-17F and IL-22 are other cytokines typically produced by
Th17 cells and may also play a role in the induction of psoriasis.
IL-17F has a strong homology with IL-17A and stimulates
proinflammatory cytokine production by epithelial cells as well
[27], whereas IL-22 has a keratinocyte proliferation-promoting
capacity [25]. Intradermal injection of IL-23 in wild-type mice
treated with IL-17A- or IL-22-blocking antibodies, or in IL-22
receptor-deficient mice, demonstrated that actually IL-22, but not
IL-17A, is responsible for the induction of acanthosis [14]. IL-22
neutralizing antibodies also prevented the development of a
psoriasis-like disease that is induced by the transfer of BALB/c
CD4
posCD45RB
hi T cells into SCID mice [28]. Furthermore, IL-
22 mRNA expression is upregulated in psoriatic skin lesions
compared to normal skin [29] and recombinant IL-22 dose-
dependently promotes acanthosis in reconstituted human epider-
mis in vitro [30], a feature most likely related to its ability to
downregulate genes involved in keratinocyte differentiation [25].
Like IL-17A, IL-22 is able to upregulate the production of
antimicrobial peptides by keratinocytes [31].
All these results point to a prominent role for the IL-23/IL-17A
pathway in the etiology of psoriasis, and many investigators have
speculated about a principal role for Th17 cells in particular.
However, we and others have shown that, in addition to CD4 Th
cells, IL-17A can also be produced by CD8 T cells, in this study
referred to as Tc17 [23,32]. CD8 T cells, which are activated in a
MHC class I-restricted fashion, are overrepresented in the
epidermis of lesional psoriatic skin [33,34]. Coincidently, MHC
class I HLA-Cw6 is one of the psoriasis susceptibility alleles
[35,36], suggesting that CD8 T cells may be involved in the
pathogenesis of psoriasis. Nevertheless, the major focus of research
has traditionally been on Th cells, thereby possibly underestimat-
ing the role of the CD8 subset. Information about the relative
proportions of CD4 and CD8 T cells capable of IL-17A and IL-22
production present in psoriatic skin compared to normal skin is
limited. To this end, we performed immunohistochemical double-
stainings to determine the presence, nature, and distribution of IL-
17 and IL-22 expressing cells in lesional psoriatic skin and healthy
normal skin in situ. To analyze the double-stained sections we used
the spectral imaging technique that offers the great advantage to
accurately display the location and abundance of each individual
chromogen, enabling to pinpoint co-localization. In addition, we
isolated and stimulated T cells from psoriatic and normal skin and
used 6 color flow cytometry to compare the percentages of IL-17A
and IL-22 producing CD4 and CD8 T cells between both
conditions. Finally, we cloned Th17 and Tc17 cells from psoriatic
dermis and epidermis to study the heterogeneity and stability of
their IL-17A and IL-22 cytokine production profile.
Materials and Methods
Ethics statement
The Medical Ethical Committee of the Academic Medical
Center has approved the use of patient’s material upon informed
written consent for the enclosed study.
Clinical material
Eight male patients (mean age 49; range 41–63) with active
psoriasis vulgaris visiting the department of Dermatology at the
Academic Medical Center in Amsterdam volunteered to partic-
ipate in this study. None of the patients used any systemic therapy
or phototherapy for at least 4 weeks prior to participation. The
mean psoriasis area and severity index (PASI) of the patients was
9.064.5. All patients gave written informed consent before
donating 5 mm punch biopsies from an active expanding plaque.
Normal adult skin was obtained from healthy subjects undergoing
plastic surgery of the breast or abdomen after informed consent.
Double-staining procedure
Sequential double alkaline phosphatase (AP) staining was
performed to identify IL-17
pos and IL-22
pos cells in 5 mm sections
from formalin-fixed paraffin-embedded biopsies from lesional
psoriatic or normal human skin. After dewaxing and heat-induced
epitope retrieval with Tris-EDTA pH 9.0 (20 min, 98uC),
specimens were stained first for IL-17 (3-step) or IL-22 (2-step)
with a polymer detection procedure. Polyclonal goat IgG anti-
human IL-17A, which has 10% cross-reactivity with IL-17F
according to the manufacturer’s data sheet, and monoclonal
mouse anti-human IL-22 were purchased from R&D Systems
Europe Ltd, Abingdon, UK. The incubation with anti-IL-17A/F
(overnight, 4uC) was followed by incubations with rabbit anti-goat
IgG and a PowerVision anti-rabbit IgG, AP-labeled polymer
(ImmunoLogic, Duiven, Netherlands). The incubation with anti-
IL-22 (overnight, 4uC) was followed by incubation with a
PowerVision anti-mouse IgG, AP-labelled polymer (ImmunoLog-
ic). Vector Blue (Vector Labs, Burlingame, CA, USA) was used as
AP reaction product. Next, all immuno-reagents used in the first
staining sequence were removed by a second heat-induced epitope
retrieval step (10 min, 98uC), leaving the blue reaction product
intact. Subsequently, the second AP staining was performed using
Liquid Permanent Red (Dako, Glostrup, Denmark) as reaction
product. To detect T cells and neutrophils we used rabbit anti-
human CD3 (Thermoscientific/LabVision, Fremont, CA, USA)
and rabbit anti-human myeloperoxidase (Dako), respectively, and
PowerVision anti-rabbit IgG, AP-labeled polymer as second step.
To detect dendritic cells and macrophages we used mouse mAb
anti-human CD11c (Monosan, Uden, The Netherlands) and
mouse mAb anti-human CD68 (Dako), respectively, and Power-
Vision anti-mouse IgG, AP-labeled polymer as second step. AP-
labeled anti-tryptase (Chemicon/Bioconnect, Huizen, The Neth-
erlands) was used to detect mast cells. Negative and ‘half’ double
staining control experiments were performed with matched species
or mouse isotype control reagents using similar immunoglobulin
concentrations.
Spectral imaging
The spectral imaging technique was applied for the exact
determination of color-colocalization to analyze all blue and red
double-stained specimens using the NUANCE
TM camera system
(Cambridge Research Instrumentation Inc., Woburn, MA, USA)
(37). First, spectral libraries of single-red (Liquid Permanent Red)
and single-blue (Vector Blue) were loaded, using ‘‘half’’ double
staining control slides. Next, these libraries were applied to the
double staining slides and subsequently the Liquid Permanent Red
and Vector Blue reaction products could be spectrally unmixed in
two individual images [37]. The Nuance software (version 2.4)
allows for the creation of a fluorescent-like image with a
pseudocoloring of the reaction product, as well as the exclusive
imaging of co-localization.
Isolation of skin T cells
Five mm punch biopsies were treated overnight at 4uC with
0.3% dispase II (Roche, Almere, Netherlands) in PBS to enable
separation of the dermis and epidermis, which were subsequently
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24-well plates to allow spontaneous migration of T cells from the
skin tissue fragments. All wells were screened microscopically for
the presence of T cells on a daily basis and a culture period of 6-7
days appeared to be optimal to allow maximum numbers of T cells
to migrate from the skin fragments.
FACS analysis
The following antibodies were used: AF-647-conjugated anti-
human IL-17A was obtained from eBioscience (San Diego, CA,
USA) and PE-conjugated anti-human IL-22 from R&D Systems
(Abingdon, UK). From BD Biosciences (Mountain View, CA,
USA) we purchased FITC-conjugated anti-human IFN-c, PerCP-
conjugated anti-CD3, PE-Cy7-conjugated anti-CD4, and APC-
Cy7-conjugated anti-CD8. Skin derived T cells were stimulated
with 100 ng/ml PMA and 1 mg/ml ionomycin in IMDM
supplemented with 10% normal human type AB serum in a 24
well plate for 5 hrs, the last 4 hr in the presence of Golgiplug (BD
Biosciences). A six color FACS analysis was performed as follows.
Cell surface staining with antibodies against CD3, CD4 and CD8
added in FACS buffer (PBS with 1% BSA and 0.05% sodium
azide) at predetermined optimal concentrations was performed
before fixation of cells for 15 min with 4% paraformaldehyde.
Cells were washed with FACS buffer twice and one more time
with PERM/WASH medium (BD Biosciences) to permeabilize
cells to allow intracellular staining. Cells were subsequently
incubated with antibodies against the cytokines and again with
antibodies to CD3, CD4 and CD8. For this purpose, appropriate
dilutions of these antibodies in PERM/WASH were incubated
with the cells for 30 min, next cells were washed twice with
PERM/WASH and one more time in FACS buffer and after
resuspension in FACS buffer measured with a FACS Calibur (BD
Biosciences). Data analysis was performed on cells within an
electronic gate set to contain the lymphocytes on basis of their
forward versus sideward scatter pattern. As a negative control,
populations were left unstimulated and subsequently stained using
the same protocol as described above.
Cloning of dermal Th17 and epidermal CD8 T cells
IL-17A-producing T cells were isolated as described by Streeck
et al [38] with some minor modifications. The IL-17A capture
complex was freshly made every time just prior to use as follows:
2 mL of a biotin-labeled CD45 antibody (clone HI30; Caltag/
Invitrogen, CA) were combined in an eppendorf tube with 20 mL
(0.5 mg/mL) of biotin-labeled IL-17A antibody (Ebiosciences) and
mixed thoroughly. Next, 2 mL (5 mg/mL) of a free avidin solution
(Invitrogen, Paisley, UK) were added and immediately mixed well.
The complex was incubated for 10 min at room temperature and
was mixed well again before use. Dermal T cells stimulated for
3.5 h with PMA and ionomycin, were washed with ice cold PBS
and resuspended in 100 mL of PBS plus 2% human serum,
whereafter the 24 mL of IL-17A capture complex were added.
After labeling for 15 min on ice, the volume was adjusted to 20 ml
with IMDM plus 10% human serum and cells were cultured in a
P75 culture flask (Corning Life Sciences, Amsterdam, The
Netherlands) for an additional two hours. Every 15 min the flask
was gently shaken. Next, cells were collected and double stained
with a fluorochrome-conjugated IL-17A antibody (Ebiosciences;
binding a different IL-17A epitope than the capture antibody) to
label the captured IL-17A, and with anti-CD4 and CD8
fluorochrome conjugated antibodies. The IL-17A
pos CD4 T cells
present within the characteristic lymphocyte gate of the forward
versus sideward scatter plot were subsequently sorted by FACS
Aria equipment (BD Biosciences) and cloned at a concentration of
1 cell/well in a 96-wells round-bottom plate. The sorted cells were
cultured in a volume of 200 mL in IMDM plus 10% human serum,
PHA (500 ng/ml), recombinant IL-2 (30 U/ml; Novartis) and IL-
15 (10 ng/ml; Pelikine) in the presence of a feeder mixture
consisting of 5610
4 allogeneic PBMC of two unrelated donors and
5610
3 EBV-transformed B cells, irradiated with 4 Gy and 8 Gy,
respectively. Due to very limited numbers the IL-17A release-
capture method could not be used for the cloning of T cells
derived from epidermal lesional skin. Unstimulated epidermal T
cells were cloned on basis of CD8 expression, without prior
assessment of their IL-17A expression potential. Wells were
screened microscopically for the presence of T cell outgrowth.
Cells from positive wells were subsequently expanded in larger
wells using the same stimulatory culture conditions but with more
feeder cells. After return to a resting phase, cells were analysed for
cytokine expression, as described above.
Statistical analysis
Statistical analysis was done using the Student t test, using SPSS
software, taking p,0.05 as significant.
Results
Abundant IL-17 and IL-22 expression by non-T cells in
lesional psoriatic skin
In order to determine the presence and distribution of IL-17
producing T cells in situ, we performed double staining on skin
sections from lesional psoriatic skin and healthy normal skin.
Spectral digital imaging was used for objective determination of
colocalization. Whereas clear IL-17
pos and CD3
pos cells could be
observed in lesional psoriatic skin (Figures 1A and 1B), only an
occasional T cell appeared to co-express IL-17. Nevertheless, the
presence of IL-17
pos T cells seemed to be a specific feature of
lesional skin, as in sections from normal skin no double stained
cells could be detected (data not shown). In order to identify the
IL-17
pos non-T cells, we performed additional double stainings.
We found that the majority of neutrophils (myeloperoxidase
positive) and virtually all mast cells (tryptase positive) in psoriatic
skin were IL-17
pos (Figures 1C and 1D). We could also detect IL-
17
pos cells in normal skin, which all appeared to be mast cells and
not neutrophils (data not shown).
Because IL-22 is generally considered as another typical Th17-
related cytokine, we determined the presence and distribution of
IL-22 as well. Although we found a clear expression of IL-22 in a
large number of cells in the inflammatory infiltrate in psoriatic
skin, we could not detect any co-expression with CD3 (Figure 1E).
Additional double stainings revealed that IL-22 was present in
some dendritic cells (CD11c) and in the majority of macrophages
(CD68) (Figures 1F and 1G, respectively), but neither in mast cells
(Figure 1H) nor in neutrophils (not shown). IL-22 expression was
also present in the same populations in normal skin (data not
shown). T cells producing IL-17 and IL-22 have been suggested to
play a prominent role in the pathogenesis of psoriasis and indeed
we were able to detect these cytokines in the psoriatic lesions in situ,
however, the remarkable observation of our immunohistochemical
analysis is that the vast majority of the cells that express these
cytokines are non-T cells.
Proportional increase of Tc17 but not Th17 cells in
psoriatic skin
We were able to detect only an occasional IL-17
pos and no IL-
22
pos T cell in lesional psoriatic skin in situ, but one should consider
that T cells only temporarily express cytokines upon activation,
that intralesional T cells are unlikely to be all in the same phase of
TC17 and TC22 in Psoriasis
PLoS ONE | www.plosone.org 3 November 2010 | Volume 5 | Issue 11 | e14108Figure 1. IL-17 and IL-22 expression in psoriatic skin. Microscopic detail of lesional psoriatic skin stained for IL-17 (A–D) or IL-22 (E–H) in
combination with CD3 (A, B, E), myeloperoxidase (C), tryptase (D, H), CD11c (F), or CD68 (G). Cytokines are visualized in blue and all different cell
markers in red. Each set of three small pictures on the right side represents a composite fluorescent-like image in pseudo-colors of the rectangle-
marked area and was obtained after unmixing the individual colors red and blue with spectral imaging. Colocalization of red and blue is indicated in
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normal skin. Consequently, in situ analysis of cytokine expression
by T cells probably represents an underestimation of the
percentage T cells with the ability to produce a cytokine of
interest. As an alternative approach to gain insight into the
percentages of IL-17A and IL-22 producing T cells, we isolated T
cells which spontaneously migrated from cultured dermal and
epidermal skin fragments and determined their ability to produce
these cytokines upon mitogenic activation in vitro. In addition, we
also studied the production of IFN-c. Six color flow cytometry was
performed to study the simultaneous expression of CD3, CD4,
CD8, IL-17A, IL-22 and IFN-c by individual cells. Representative
cytokine expression profiles of CD3 populations from the dermal
component of psoriatic and normal skin are shown in the FACS
dot plots in Figure 2. The proportions of dermal CD4 and CD8 T
cells expressing distinct cytokine profiles are shown in Figure 3.
Dermal T cells derived from psoriatic skin, as well as from normal
skin, consistently contained a substantial percentage of IL-17A
producers, indicating that the presence of IL-17A
pos T cells is not
restricted to lesional skin (Figures 2 and 3). Some IL-17A
pos T cells
coproduced IL-22, consistent with what has been described for
mouse as well as human Th17 cells. On the other hand, all dermal
T cell samples from both lesional and normal skin contained T
cells which produced IL-22 in the absence of IL-17A and IFN-c,
representing the recently defined Th22 cells and their CD8
‘‘Tc22’’ counterparts (Figures 2 and 3). Only a minority of IL-17A
and/or IL-22 producing T cells displayed IFN-c production as
well and could be distinguished in most samples (Figures 2 and 3).
T cells producing IFN-c in the absence of IL-17A and IL-22, in
our study referred to as Th1 and Tc1 cells, accounted for the
highest percentage of dermal T cells in both lesional and normal
skin (Figures 2 and 3).
When the cytokine profiles of dermal CD4 and CD8 T cell
subsets were analyzed separately, we found, surprisingly, that the
proportions of Th17 cells were very similar in psoriatic dermis
compared to normal dermis (Figure 3A). This held true for Th17
cells that only produced IL-17A (psoriatic skin: 5.94%61.13;
normal skin: 5.87%61.83%) and for Th17 cells that coproduced
IL-22 (psoriatic skin: 2.36%60.72%; normal skin: 2.05%60.95%)
or IFN-c (psoriatic skin: 0.33%60.12%; normal skin:
0.84%60.41%). Obviously, in contrast to the percentage, the
absolute number of Th17 cells is still much higher in psoriatic skin
as it is more densely populated with T cells [6]. In both psoriasis
patients and healthy individuals the total percentage of Th17 cells
exceeded that of Tc17 cells (psoriatic skin: Th17 8.89%61.88%,
Tc17 3.39%60.70%; normal skin: Th17 9.18%63.13%; Tc17
0.35%60.17%), which is consistent with our data on IL-17A
expression by T cells in peripheral blood (unpublished observa-
tion). Remarkably, the dermal CD8 T cell population from
psoriatic skin contained a significantly increased percentage of
Tc17 cells (psoriatic skin: 3.39%60.70%; normal skin:
0.35%60.17%). This was not only the case for the IL-17A single
producers, but also for Tc17 cells coproducing IL-22 (Figure 3B).
Moreover, and further underlining a possible role of Tc17 cells in
the pathogenesis of psoriasis, the epidermis contained an even 2 to
10 fold higher frequency of Tc17 cells than the adjacent dermis.
This was observed in all four psoriasis patients from whom we had
obtained enough epidermal T cells for analysis (Figure 4). In
contrast, the population of T cells derived from the epidermis and
adjacent dermis of normal skin contained similar low levels of
Tc17 cells. Th17 cells were present in substantial numbers in the
epidermis from both psoriatic and normal skin, but no consistent
pattern of increase/decrease relative to the corresponding dermis
was observed (Figure 4).
Proportional increase of IL-17A
neg IFN-c
neg IL-22
pos CD8
T cells in psoriatic skin
Because of its property to promote acanthosis, IL-22 is highly
relevant for the pathogenesis psoriasis. Although IL-22 has been
associated with Th17 cells, recent publications indicate that IL-22
producing CD4 T cells exist that lack concomitant expression of
IL-17A and IFN-c and may represent a distinct functional T cell
subset, named Th22 [39,40]. In analogy, IL-22 producing CD8 T
cells that lack IL-17A and IFN-c can be termed Tc22. The dermal
T cells of lesional psoriatic and normal skin contained similar
percentages of Th22 cells (psoriatic skin: 3.70%60.68%; normal
skin: 3.90%60.60%), but remarkably, the frequency of Tc22 cells
was substantially increased in lesional skin (psoriatic skin:
2.85%61.58%; normal skin 0.16%60.07%). One patient was
remarkable in this respect as 14% of the skin derived dermal CD8
T cells consisted of Tc22 cells, suggesting that a specific expansion
of these T cells has taken place in the inflamed skin of this patient.
As was the case with IL-17A
pos CD8 T cells, also the percentage of
IL-22
pos CD8 T cells was much higher in the epidermis than in the
adjacent dermis of psoriatic skin, but not in normal skin (Figure 4),
underlining a possible role of IL-17A and IL-22 producing CD8 T
cells in the pathogenesis of psoriasis. With regard to the well-
known prominent role of IFN-c in the etiology of this disease, we
unexpectedly observed no increased frequencies of IFN-c
producing CD4 or CD8 T cells in the dermis of psoriasis patients
compared to healthy skin donors. A comparison of IFN-c
expression in epidermal versus adjacent dermal T cell populations
was only determined for three patients. In two of them the
percentages of IFN-c
pos T cells in both CD4 and CD8 subsets
were similar, whereas in one patient there was about a two fold
increase in the percentage of both CD4 and CD8 IFN-c
expressing T cells in the epidermal compared to the dermal
compartment (data not shown).
Cells with a Th22 and Tc22 cytokine profile derived from
Th17 and Tc17 cells, respectively
One may question whether the cytokine patterns of the skin-
infiltrating T cells are stable and transferred to the progeny after
cell division. To investigate this for IL-17A producers in particular,
we cloned psoriatic dermal Th17 cells which were purified by
FACS sorting on the basis of an IL-17A release-capture assay. This
technique could not be used when we cloned T cells from the
corresponding epidermis, because of the limited number of
epidermal T cells. In that case we purified T cells on basis of
CD8 cell surface expression and twelve out of fifteen of the
epidermal CD8 T cell clones turned out be IL-17A producers,
consistent with our observation that epidermal CD8 T cells from
psoriatic skin contain high percentages of Tc17 cells. The
remaining three epidermal T cell clones expressed IFN-c only,
without IL-17A or IL-22, thus representing Tc1 clones. All cells
within individual clones displayed the same T cell receptor V-beta
yellow. Spectral imaging analysis of this double-stained series of sections clearly shows the presence of an occasional IL-17
pos T cell in psoriatic
lesions, whereas IL-22
pos T cells were absent. The IL-17 expression in psoriatic skin was predominantly confined to neutrophils and mast cells and IL-
22 was highly expressed in many dendritic cells and in most macrophages. The figure is representative of the results from three different donors.
Examples of double-stained cells are indicated with an arrow and single-stained cells with an arrowhead. Original magnification 2006.
doi:10.1371/journal.pone.0014108.g001
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cell clones, each originating from a different single IL-17A-
expressing T cell, were found to still produce IL-17A after culture
for one month. Unexpectedly however, in five of these Th17
clones a variable proportion (range 5–25%) of cells did produce
IL-22 but lacked IL-17A, and in addition, part of these IL-
17A
negIL-22
pos T cells lacked IFN-c as well, indicating that some
cells had acquired a Th22 profile (Figure 5). This suggests a
developmental relationship between Th17 and Th22 cells and it is
not inconceivable that Th22 cells may originate from Th17
precursors in vivo. Likewise, a proportion of cells with a Tc22
cytokine profile were found in six out of twelve of the IL-17A
producing epidermal CD8 T cell clones derived from the same
skin biopsy (Figure 5). Taken all together, our results suggest that
CD4 and CD8 T cells in psoriatic skin have a certain degree of
plasticity in their cytokine production pattern.
Figure 2. Cytokine expression in skin derived dermal T cells after in vitro stimulation. T cells with the ability to produce IL-17A and/or IL-
22 and/or IFN-c are present in the dermis of both psoriatic and normal skin. Bulk T cells derived from the dermis were stimulated with PMA and
ionomycin and stained for cell surface expression of CD3, CD4 and CD8 and intracellular expression of IL-17A, IL-22 and IFN-c. Dot-plots contain the
CD3 cells within the lymphocyte gate. This analysis shows the presence among dermal CD3 T cells of both normal and psoriatic skin of single and
double producers of IL-17A, IL-22 and IFN-c. Results are representative for eight independent experiments.
doi:10.1371/journal.pone.0014108.g002
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Because recent experimental findings suggest an important role
for IL-17A and IL-22 producing T cells in the pathogenesis of
psoriasis, we focused in this study on these types of T cells and
studied their relative proportion in the CD4 and CD8 skin resident
T cell population in psoriatic skin and normal skin. Thus far, most
studies have speculated about a possible role for Th17 cells, i.e.
CD4 T cells which, in addition to key cytokine IL-17A, also have
been described to be able to produce IL-22. In contrast to
Figure 3. Cytokine profiles of dermis-derived CD4 and CD8 bulk T cell populations. Relative contribution of T cells with different
expression profiles of IL-17A, IL-22 and IFN-c production among in vitro activated dermal CD4 T cells (a) and CD8 T (b) from psoriatic skin (closed
symbols) versus normal skin (open symbols). Each series of a particular symbol represents data from one individual. Specifically T cells with the ability
to produce IL-17A and/or IL-22 are present in increased percentages of the CD8 T cell population in lesional skin compared to normal skin. *P,0.05;
**P,0.01 Depicted data show the results obtained by six color flow cytometry of the eight independent experiments.
doi:10.1371/journal.pone.0014108.g003
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normal skin contain similar frequencies of Th17 cells. This
observation does not necessarily imply, however, that these cells
have no role in the pathogenesis of psoriasis, but only suggest that
Th17 cells do not expand in the lesional skin. On the other hand,
because the density of T cells is much higher in psoriasis lesions
[6], our results also imply that psoriatic skin does contain an
increase in absolute numbers of Th17 cells per mm
2. Of note, we
found that percentages of Th17 cells are generally higher in the
skin than in peripheral blood in both patients and healthy
individuals (unpublished observation), which would indicate that
Th17 cells preferentially home into the skin.
To our surprise, our results show unequivocally that, compared
to normal skin, psoriatic skin contains a T cell infiltrate with a
significantly increased percentage of Tc17 cells, i.e. CD8 T cells
with the ability to produce IL-17A alone or in combination with
IL-22. This indicates that this subset either shows a preferential
homing to the lesions in psoriasis patients or proliferates at these
sites after being activated, possibly as a result of recognition of
locally presented antigen(s). This selective increase in the
proportion of Tc17 cells in psoriatic skin, which is even more
striking in the epidermis than the dermis, reinforces the concept
that CD8 T cells may be important in the pathogenesis of
psoriasis, as has been suggested earlier [33,34]. Psoriatic epidermis
is known to contain a significantly higher CD8 to CD4 T cell ratio
than the dermis [34,41] and also a strong association of psoriasis
with HLA-Cw6 has been reported [35,36], a MHC class I
molecule involved in antigen presentation to CD8 T cells. In this
respect, it is interesting to note that our patient with the relatively
high proportion of IL-17A and/or IL-22-producing CD8 dermal
T cells coincidently has a HLA-Cw6 phenotype (data not shown).
It is tempting to speculate that these CD8 T cells may have
responded specifically to (auto)-antigenic peptides presented on
skin cells in the context of HLA-Cw6. With regard to this concept,
it is interesting to note that CD8 skin homing, peripheral blood T
cells in HLA-Cw6
pos psoriasis patients were shown to display an
increased reactivity (IFN-c production) against peptides derived
from keratin 17, which is produced by keratinocytes at elevated
levels in psoriatic skin [42]. These peptides were chosen on basis of
homology between keratin 17 and streptococcal M protein and
selected for HLA-Cw6 binding. Since psoriasis is sometimes
initiated or exacerbated by a throat infection with streptococci and
M protein is an important antigenic determinant, the authors
speculate that T cells triggered by streptococcal proteins can cross-
react with components from the lesional skin [42]. It would be
interesting to find out whether psoriatic plaques derived CD8 T
cells also show keratin 17 directed responses.
Recently, also other studies have compared IL-17A producing
T cells derived from psoriatic and normal skin. One group
reported a similar percentage of IL-17A
pos CD3 T cells in psoriatic
dermis (mean 6% versus 7% in our study), but they found a much
lower percentage of IL-17A
pos CD3 T cells (0.5% versus 6%) and
IL-17A
pos CD4 T cells (1% versus 9%) in normal dermis [25,43].
In another study, data were expressed as absolute numbers of
Th17 or Tc17 cells per mm
2 skin, which were both increased in
psoriatic dermis [44]. However, it was left unmentioned whether
also in that study only the Tc17 cells displayed a proportional
increase in the psoriatic dermal T cell population. Interestingly,
and also in line with our results, it was reported that the increase of
Tc17 cells in absolute cell numbers was most pronounced in the
Figure 4. Proportions of IL-17A and IL-22 producing T cells in the epidermis versus dermis. The increase in the percentages of Tc17 and
IL-22 producing CD8 T cells is even more pronounced in the psoriatic epidermis than in the psoriatic dermis, whereas normal epidermis and dermis
are almost devoid of such T cells (n=4).
doi:10.1371/journal.pone.0014108.g004
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normal epidermis and dermis [44]. In contrast to their findings, we
observed that the epidermis contains substantial numbers of Th17
cells in both patients and healthy controls.
We found that part of CD4 as well as CD8 T cells from lesional
psoriatic skin and normal skin produced IL-22 in the absence of IL-
17A. The vast majority of IL-17A
negIL-22
pos cells turned out to be
IFN-c
neg as well. Two recent publications have shown that CD4 T
cells with such features represent a functionally distinct Th22 subset
that is different from Th17 cells [39,40]. Whether CD8 T cells that
generate IL-22 without IL-17A and IFN-c also make up a separate
Tc22 cell subset still awaits further investigation. Nevertheless, our
finding that the frequency of Tc22 cells was also increased in
psoriatic dermis may well be of importance in the pathogenesis of
psoriasis, because of the keratinocyte proliferation-promoting
activity of this cytokine. The origin of IL-22 single-producing T
cells is unknown to date, but our results suggest that at least part of
these cells may derive from Th17 and Tc17 cells, as we found that
some of our IL-17A producing CD4 and CD8 T cell clones
contained a proportion of cells producing IL-22 but lacking IL-17A
and IFN-c. Apparently, at least in vitro, daughter cells from IL-17A
producing T cells can lose the capacity to express IL-17A and
develop into IL-22 single-producing T cells. In this respect, it is
interesting to note that the patient with the highest percentage of
Tc22 cells also contained the highest percentage of Tc17 cells in the
bulk dermal T cell population.
Many studies have addressed the potential role of IFN-c in the
etiology of psoriasis. Elevated IFN-c mRNA levels in psoriatic skin
are indicative for a local production of this cytokine and can
explain the observed upregulation in the expression of many
immune response genes in psoriatic lesions. In addition, IFN-c can
stimulate keratinocytes and antigen-presenting cells to produce IL-
1b and IL-23 and thus promote the expansion of IL-17A
producing T cells. Although lesional psoriatic skin does contain
larger numbers of cutaneous T cells than normal skin _ and
accordingly more IFN-c producing T cells _ we did not find a
proportional increase in the percentage of IFN-c expressing T cells
in psoriatic dermis compared to normal dermis, irrespective of co-
expression of IL-17A and/or IL-22. Comparison of the T cells
from the psoriatic epidermis versus the adjacent dermis revealed
an increase in the percentages of IFN-c
pos T cells in both CD4 and
CD8 subsets in the psoriatic epidermis in one out of three patients.
Larger numbers of experiments are necessary to evaluate the
contribution of epidermal IFN-c producing T cells in the
development of psoriasis.
In our attempt to identify IL-17
pos T cells in skin in situ,w e
demonstrated that numerous IL-17
pos cells were present in
psoriasis lesions, but that only an occasional IL-17
pos cell could
be identified as a T cell, suggesting that at the time of biopsy taking
only a minor part of the IL-17
pos T cells present in the psoriatic
skin were activated. We believe that we did not stain receptor-
bound IL-17, as keratinocytes, which do express IL-17 receptors,
Figure 5. Cytokine profile of psoriatic skin derived Th17 and Tc17 clones. IL-17A
pos CD4 and CD8 T cell clones (Th17 and Tc17, respectively)
from psoriatic skin have the ability to give rise to a proportion of IL-22 producing cells that lack IL-17A and IFN-c expression (the putative Th22 and
Tc22, respectively). IL-17A
pos CD4 dermal T cells and CD8 epidermal T cells derived from psoriatic skin were cloned and subsequently assayed for
intracellular IL-17A, IL-22, and IFN-c after PMA ionomycin stimulation. Representative examples of CD4 and CD8 T cell clones are given. Part of the
cells within the CD4 Th17 clone expressed IL-22, but lacked both IL-17A (right-bottom quadrant in the upper dot-plot) and IFN-c expression
(associated histogram indicated by arrow), a cytokine pattern typical of Th22 cells. Likewise, part of the cells of the CD8 Tc17 clone (bottom dot-plot)
lacked IL-17A and IFN-c expression, which is a Tc22 cytokine profile.
doi:10.1371/journal.pone.0014108.g005
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immunohistochemistry is consistent with the high levels of IL-17
mRNA detected previously by RT-PCR [23,24]. Our FACS data
showed that, even after optimal stimulation in vitro, IL-17A
expressing T cells generally represent less than 10% of the dermal
T cell population from psoriatic skin. In addition, it is not to be
expected that all Th17 and Tc17 cells will be simultaneously and/
or continuously activated in skin in situ, therefore the presence of
low numbers of IL-17
pos T cells in the skin sections appears
reasonable. It was quite remarkable to observe that mast cells and
neutrophils were the major cell types stained with our polyclonal
anti-IL-17 antibody in the inflamed skin. This same reagent was
used in recent studies to demonstrate that in the inflamed
synovium of rheumatoid arthritis patients and in lesional tissue of
atherosclerotic patients mast cells also represent an important
source of IL-17 expression [45,46]. Mast cells have been reported
to produce IL-17F but not IL-17A and since our polyclonal Ab
that recognizes IL-17A has crossreactivity to IL-17F according to
the manufacturer, it is likely that a considerable part of the IL-17
we detected in human skin mast cells was IL-17F actually [46,47].
On the same line, it has been reported that IL-17A producing T
cells most often also produce IL-17F, sometimes even as a
heterodimer, and also neutrophils can produce both IL-17A and
IL-17F [48]. As concerned the IL-17
pos T cells and neutrophils in
the stained skin sections, we do not know whether IL-17A or IL-
17F or both were detected. Both cytokines are proinflammatory
and may have a role in the pathogenesis of psoriasis, as both have
features in common among others their ability to activate
keratinocytes [49,50].
Another surprising observation from our double-stained skin
sections was that IL-22 was solely detected in non-T cells
belonging to the myeloid lineage such as CD68
pos macrophages
and CD11c
pos dendritic cells. Psoriatic lesions are not only
characterized by an increase in T cells, but also in CD11c
pos
dendritic cells. This increase specifically concerns the CD1c
neg
TNF-a and iNOS expressing so-called ‘‘inflammatory’’ or TipDC
and not the CD1c
pos dermal DC, which are also present in normal
skin [51]. At the moment we do not know whether our
CD11c
posIL-22
pos cells are TipDC or dermal DC.
As both IL-17A and IL-22 have been implicated as crucial
cytokines in the pathogenesis of psoriasis, our immunohistochem-
istry data suggest that, in addition to T cells, also other IL-17
pos
and/or IL-22
pos cells may be relevant to this chronic skin disease
and possible targets for intervention in psoriasis therapy. As
mentioned earlier, the increase we have observed in the
percentage of CD8 T cells with the potential to produce IL-17A
and/or IL-22 in psoriatic skin suggests an antigen-driven
expansion of these T cells at the site of inflammation, but their
precise role in the pathogenesis of psoriasis still requires more
investigation. It could well be that activated Tc17 cells and Tc22
cells, in addition to IL-17A and IL-22, produce other yet
undiscovered mediators that are involved in the inflammatory
process in the psoriasis plaques. Recently, the potential role of
CD8 T cells in the etiology of other human diseases has been
reevaluated, such as in systemic sclerosis [52], multiple sclerosis
[53] and atopic dermatitis [32]. Here we provide support for
involvement of Tc17 and Tc22 cells in the pathogenesis of
psoriasis underlining that the common interest in these cells has
wrongly been largely ignored. Exploring their antigen reactivity
may well be of great importance to find out whether these CD8 T
cell subsets respond to components from the inflamed skin in a
HLA-Cw6 restricted fashion, which would make these cells even
more relevant as potential targets for immunotherapy.
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